Drug-Eluting Vascular Stent System
Restenosis following nitinol stenting peaks at about 12 months in the SFA.
Proven Drug-Delivery Technology with Sustained Release
Polymer-based technology with proven biocompatibility
The Eluvia Stent uses the same fluoropolymer as the PROMUS™ and XIENCE™ coronary stents which have a proven history of safety in the body.
- More than 20 million implants1
- More than 100,000 patients studied2
- Data on file at Boston Scientific. Represents total global sales of the PROMUS (Boston Scientific) and XIENCE (Abbott) stents since 2006.
- Data on file at Boston Scientific. Represents total population of patients studied in the PROMUS and XIENCE series of clinical trials.
Eluvia sustains drug concentrations in the lesion to match the restenotic process in the SFA
- Based on preclinical pharmacokinetic analysis for Zilver PTX. Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.
- Based on preclinical pharmacokinetic analysis for three Drug-Coated Balloons (IN.PACT Pacific, Lutonix, Ranger). Gongora CA, et al. JACC Cardiovasc Interv. 2015 Jul;8(8):1115-1123. doi: 10.1016/j.jcin.2015.03.020.
- Based on preclinical pharmacokinetic analysis for Eluvia. Data on file at Boston Scientific.
Built on the Innova™ Stent platform, designed to provide uniform scaffolding for drug delivery while optimizing:
- Radial strength
- Fracture resistance